{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P13236",
      "entity_text" : "MIP-1beta",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ07371",
      "entity_text" : "Fenbrutinib",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Fenbrutinib, which is a reversible BTK inhibitor, significantly decreased CXCL13 and MIP-1beta (CCL4) (Morimoto A, et al. EULAR 2019 [abstract FRI0129]; 14 June 2019; Madrid, Spain).",
  "reading_complete" : "2020-07-28T16:59:33Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T16:55:57Z",
  "trigger" : "decreased",
  "evidence" : [ "Fenbrutinib, which is a reversible BTK inhibitor, significantly decreased CXCL13 and MIP-1beta" ],
  "pmc_id" : "7021855",
  "score" : 0
}